0.0001 -0 (-66.67%) | 07-18 13:41 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0 | 1-year : | 0 |
Resists | First : | 0 | Second : | 0 |
Pivot price | 0 ![]() |
|||
Supports | First : | 0 | Second : | 0 |
MAs | MA(5) : | 0 ![]() |
MA(20) : | 0 ![]() |
MA(100) : | 0 | MA(250) : | 0 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 0 | D(3) : | 0 |
RSI | RSI(14): 4.6 | |||
52-week | High : | 0.07 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MOTS ] has closed above bottom band by 0.0%. Bollinger Bands are 342.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 0 - 0 | 0 - 0 |
Low: | 0 - 0 | 0 - 0 |
Close: | 0 - 0 | 0 - 0 |
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Thu, 20 Jun 2024
Motus GI faces default notice after board decision - Investing.com
Fri, 12 Apr 2024
Why Is Motus GI (MOTS) Stock Down 37% Today? - InvestorPlace
Mon, 18 Mar 2024
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Thu, 22 Feb 2024
Motus GI raises $2.7M through warrant exercise, plans growth By Investing.com - Investing.com India
Mon, 11 Dec 2023
Cigna (CI) Adds $10B to Buyback Funds, Turns to Bolt-On Buyouts - Nasdaq
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
OTC
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | -4 (M) |
Shares Float | 0 (M) |
Held by Insiders | 6.39e+006 (%) |
Held by Institutions | 5.72e+006 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -2.97 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 165.6 % |
Return on Equity (ttm) | -62.1 % |
Qtrly Rev. Growth | 69 % |
Gross Profit (p.s.) | -27.54 |
Sales Per Share | -302.9 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -9.14e+006 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | -0.01 |
Price to Sales | -0.01 |
Price to Cash Flow | 0 |
Dividend | 23240 |
Forward Dividend | 80930 |
Dividend Yield | 23240000000% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |